Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.
Elizabeth Williams
CEO and co-founder, Hemideina
Contacter l'équipe de la transaction
Ryan Whitelegg
Oaklins Henslow
Transactions connexes
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
En apprendre plusMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
En apprendre plusQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
En apprendre plus